Skip to content

Precigen PGEN EPS (Basic)

EPS (Basic) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+8.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$6.99-7.8%
Gilead Sciences logo
Gilead SciencesGILD
$1.63+53.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$1.15-5.5%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$1.69-9.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$1.06-11.6%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.93B+213%

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's EPS (basic)?
Precigen (PGEN) reported EPS (basic) of -$0.02 in Q1 2026.
How has Precigen's EPS (basic) changed year-over-year?
Precigen's EPS (basic) increased by 88.9% year-over-year, from -$0.18 to -$0.02.
What is the long-term trend for Precigen's EPS (basic)?
Over 3 years (2021 to 2025), Precigen's EPS (basic) has grown at a 41.8% compound annual growth rate (CAGR), from -$0.47 to -$1.34.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.